The FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced. An atypical antipsychotic ...

The Federal Court found that Teva’s product would incorporate all essential elements of the prefilled syringes claims and Swiss-style claims and that, should Teva come to market and sell its ...

Meeting Coverage > Psych Congress Video Pearls Low Relapse Rates With Twice-Yearly Schizophrenia Treatment — Every-6-month dosing of paliperidone palmitate was effective and safe up to 3 years ...

The 335 patent relates to dosing regimens for paliperidone palmitate depot (long-acting) formulations for the treatment of schizophrenia.

Paliperidone has a prolactin-elevating effect similar to that seen with risperidone, a drug that is associated with higher levels of prolactin than other antipsychotic drugs.

This study compares the efficacy and tolerability of paliperidone extended-release with risperidone immediate-release in the treatment of schizophrenia, using propensity score methodology.

Paliperidone extended release, a new chemical entity, is the first antipsychotic to use the extended release technology, which provides a steady release of medication over a 24-hour period.

Invega Hafyera is supplied as 1092mg/3.5mL and 1560mg/5mL paliperidone palmitate in a kit containing a single-dose prefilled syringe and safety needles.

The FDA has approved extended-release paliperidone for the treatment of schizophrenia in adolescents.

INVEGA TRINZA prescription and dosage information for physicians and health care professionals. Pharmacology, adverse reactions, warnings, and INVEGA TRINZAside effects.